Heartflow Inc.

11/06/2022 | Press release | Archived content

Late-breaking Data Demonstrate AHA/ACC Guideline-directed CCTA + FFRCT Precision Pathway is Superior to Traditional Testing

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Heartflow Inc. published this content on November 06, 2022, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 15, 2025 at 15:45 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]